Aclaris Therapeutics, Inc. (ACRS) Institutional Ownership

Ownership Summary

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has 119 institutional investors with active 13F positions as of December 2025.

• They owned 70.2% of outstanding stock in December 2025, down from 70.5% the prior quarter.
• Their total shares held in ACRS increased 0.18% from the prior quarter, while the number of investors in Aclaris Therapeutics increased 22.68% year over year.
• During the quarter, 58 of these 119 funds increased positions in ACRS, 40 reduced exposure, and 21 held steady.
• Institutional investors collectively held 86.11Mn shares in Aclaris Therapeutics as of December 2025, up by 152.33K shares quarter on quarter, and down 3.34Mn shares year over year.
• As of December 31, 2025, BML Capital Management, LLC held the largest stake in Aclaris Therapeutics with 14.25Mn shares, accounting for 11.62% of total shares outstanding.
• Top purchasers of ACRS stock for the quarter ending December 2025 included Deep Track Capital, LP (9.34Mn), RA CAPITAL MANAGEMENT, L.P. (6.8Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.17Mn), Frazier Life Sciences Management, L.P. (4.93Mn), BALYASNY ASSET MANAGEMENT L.P. (3.36Mn).
• The largest sales of ACRS for the quarter ending December 2025 came from Vivo Capital, LLC (2.22Mn), NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO (1.9Mn), D. E. Shaw & Co., Inc. (1.2Mn), ADAR1 Capital Management, LLC (1.1Mn), Goldman Sachs Group Inc (676.31K).
• Business Quant data shows the 10 biggest positions in Aclaris Therapeutics as of December 2025 are held by BML Capital Management, LLC (14.25Mn), Deep Track Capital, LP (9.34Mn), BlackRock, Inc. (7.41Mn), RA CAPITAL MANAGEMENT, L.P. (6.8Mn), Vivo Capital, LLC (6.67Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.17Mn), Frazier Life Sciences Management, L.P. (4.93Mn), Rock Springs Capital Management LP (4.47Mn), Decheng Capital LLC (4.04Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.87Mn).